Financials

Abbott Laboratories financials

ABT Health Care Equipment and Supplies

Abbott Laboratories, founded in 1888 and headquartered in Abbott Park, Illinois, United States, is a diversified global healthcare company offering diagnostics, medical devices, nutrition, and branded generic pharmaceuticals. The company reported revenues over $43 billion in fiscal 2022, supported by innovative products like the FreeStyle Libre and Alinity diagnostic platforms. Under the leadership of CEO Robert B. Ford since March 2020, Abbott has strengthened its position in more than 160 countries. Looking ahead, it is investing in next-generation digital health and expanding its global footprint to meet evolving market needs.

Snapshot

Abbott Laboratories reported $44.33B in revenue in fiscal 2025, up 5.7% year over year, with an operating margin of 18.2%.

Revenue (FY2025): $44.33B
YoY growth: +5.7%
Operating margin: 18.2%
Direction: Expanding

Financial statements

In thousands, USD · annual

In thousands, USD
	FY 2025	FY 2024	FY 2023	FY 2022
Total Revenues	44,328,000	41,950,000	40,109,000	43,653,000
Cost of Sales	19,319,000	18,706,000	17,975,000	19,142,000
Gross Profit	25,009,000	23,244,000	22,134,000	24,511,000
Selling, General & Administrative Expenses	12,332,000	11,697,000	10,949,000	11,248,000
Depreciation & Amortization Expenses	1,682,000	1,878,000	1,966,000	2,013,000
Research & Development Expenses	2,942,000	2,844,000	2,741,000	2,888,000
Operating Profit	8,053,000	6,825,000	6,478,000	8,362,000
Interest and Investment Income	308,000	344,000	385,000	183,000
Interest Expense	(493,000)	(559,000)	(637,000)	(558,000)
Non-Operating Income	598,000	403,000	438,000	319,000
Total Non-Operating Income	413,000	188,000	186,000	(56,000)
Income Before Provision for Income Taxes	8,466,000	7,013,000	6,664,000	8,306,000
Provision for Income Taxes	1,942,000	(6,389,000)	941,000	1,373,000
Consolidated Net Income	6,524,000	13,402,000	5,723,000	6,933,000
Net Income Attributable to Common Shareholders	6,524,000	13,402,000	5,723,000	6,933,000
Basic EPS	3.73	7.67	3.28	3.94
Diluted EPS	3.72	7.64	3.26	3.91
Basic Weighted Average Shares Outstanding	1,741,000	1,740,000	1,740,000	1,753,000
Diluted Weighted Average Shares Outstanding	1,748,000	1,748,000	1,749,000	1,764,000
Shares Outstanding	1,736,600	1,731,700	1,734,080	1,737,800

In thousands, USD
	FY 2025	FY 2024	FY 2023	FY 2022
Cash and Cash Equivalents	8,522,000	7,616,000	6,896,000	9,882,000
Short-Term Investments	417,000	351,000	383,000	288,000
Total Cash and Cash Equivalents	8,939,000	7,967,000	7,279,000	10,170,000
Accounts Receivable	7,929,000	6,925,000	6,565,000	6,218,000
Other Receivables	2,640,000	2,570,000	2,256,000	2,663,000
Total Trade Receivables	10,569,000	9,495,000	8,821,000	8,881,000
Inventories	6,488,000	6,194,000	6,570,000	6,173,000
Other Current Assets	2,640,000	2,570,000	2,256,000	2,663,000
Total Current Assets	25,996,000	23,656,000	22,670,000	25,224,000
Net Property, Plant & Equipment	37,038,000	33,398,000	32,087,000	29,374,000
Net Intangible Assets	5,526,000	6,647,000	8,815,000	10,454,000
Goodwill	24,035,000	23,108,000	23,679,000	22,799,000
Long-Term Investments	918,000	886,000	799,000	766,000
Other Long-Term Assets	18,422,000	16,459,000	7,097,000	6,033,000
Total Assets	86,713,000	81,414,000	73,214,000	74,438,000
Accounts Payable	4,240,000	4,195,000	4,295,000	4,607,000
Accrued Expenses	7,557,000	6,844,000	7,019,000	7,401,000
Current Portion of Long-Term Debt	3,033,000	1,500,000	1,080,000	2,251,000
Other Current Liabilities	1,666,000	1,618,000	1,447,000	1,230,000
Total Current Liabilities	16,496,000	14,157,000	13,841,000	15,489,000
Long-Term Debt	9,896,000	12,625,000	13,599,000	14,522,000
Other Long-Term Liabilities	7,550,000	6,731,000	6,947,000	7,522,000
Total Long-Term Liabilities	17,446,000	19,356,000	20,546,000	22,044,000
Total Liabilities	33,942,000	33,513,000	34,387,000	37,533,000
Common Stock	25,527,000	25,153,000	24,869,000	24,709,000
Treasury Stock	(17,177,000)	(16,844,000)	(15,981,000)	(15,229,000)
Accumulated Other Comprehensive Income	(6,001,000)	(7,906,000)	(7,839,000)	(8,051,000)
Retained Earnings	49,781,000	47,261,000	37,554,000	35,257,000
Total Common Shareholders' Equity	52,130,000	47,664,000	38,603,000	36,686,000
Minority Interests and Other	641,000	237,000	224,000	219,000
Total Shareholders' Equity	52,771,000	47,901,000	38,827,000	36,905,000
Total Liabilities and Shareholders' Equity	86,713,000	81,414,000	73,214,000	74,438,000

In thousands, USD
	FY 2025	FY 2024	FY 2023	FY 2022
Net Income	6,524,000	13,402,000	5,723,000	6,933,000
Depreciation & Amortization	3,116,000	3,218,000	3,243,000	3,267,000
Share-Based Compensation Expense	664,000	673,000	644,000	685,000
Other Adjustments	65,000	482,000	126,000	215,000
Changes in Trade Receivables	(652,000)	(691,000)	(356,000)	(68,000)
Changes in Inventories	195,000	(58,000)	(232,000)	(1,413,000)
Changes in Accounts Payable	954,000	356,000	(760,000)	420,000
Changes in Income Taxes Payable	(5,000)	(8,028,000)	(585,000)	(383,000)
Changes in Other Operating Activities	(1,295,000)	(796,000)	(542,000)	(75,000)
Cash from Operating Activities	9,566,000	8,558,000	7,261,000	9,581,000
Capital Expenditure	(2,171,000)	(2,207,000)	(2,202,000)	(1,777,000)
Purchases of Investments	(167,000)	(169,000)	(159,000)	(185,000)
Proceeds from Sale of Investments	3,000	28,000	43,000	152,000
Payments for Business Acquisitions	(105,000)	—	(877,000)	—
Proceeds from Business Divestments	—	1,000	40,000	48,000
Other Investing Activities	18,000	9,000	22,000	22,000
Cash from Investing Activities	(2,422,000)	(2,338,000)	(3,133,000)	(1,740,000)
Issuance of Long-Term Debt	5,000	223,000	2,000	7,000
Repayments of Long-Term Debt	(1,504,000)	(660,000)	(2,498,000)	(753,000)
Net Issuance / (Repayments) of Long-Term Debt	(1,499,000)	(437,000)	(2,496,000)	(746,000)
Issuance of Common Shares	396,000	264,000	167,000	167,000
Repurchases of Common Shares	(893,000)	(1,295,000)	(1,227,000)	(3,795,000)
Net Issuance / (Repurchases) of Common Shares	(497,000)	(1,031,000)	(1,060,000)	(3,628,000)
Common Share Dividends Paid	(4,116,000)	(3,836,000)	(3,556,000)	(3,309,000)
Other Financing Activities	(197,000)	(100,000)	21,000	47,000
Cash from Financing Activities	(6,309,000)	(5,404,000)	(7,091,000)	(7,636,000)
Effect of Exchange Rate Changes on Cash and Cash Equivalents	71,000	(96,000)	(23,000)	(122,000)
Increase / (Decrease) in Cash, Cash Equivalents and Restricted Cash	906,000	720,000	(2,986,000)	83,000

Quarterly trend

last 8 quarters

Quarter	Revenue	YoY growth	Operating margin	Operating income
Q1 2026	$11.16B	+7.8%	12.0%	$1.34B
Q4 2025	$11.46B	+4.4%	19.6%	$2.25B
Q3 2025	$11.37B	+6.9%	18.1%	$2.06B
Q2 2025	$11.14B	+7.4%	18.4%	$2.05B
Q1 2025	$10.36B	—	16.3%	$1.69B
Q4 2024	$10.97B	—	17.4%	$1.91B
Q3 2024	$10.63B	—	17.5%	$1.86B
Q2 2024	$10.38B	—	16.1%	$1.67B

Revenue by quarter$M

$10.38B

Q2 '24

$10.63B

Q3 '24

$10.97B

Q4 '24

$10.36B

Q1 '25

$11.14B

Q2 '25

$11.37B

Q3 '25

$11.46B

Q4 '25

$11.16B

Q1 '26

56.4%

Gross margin

18.2%

Operating margin

14.7%

Net margin

SourceCompany financial filings (income statement, balance sheet, cash flow) Last updated2026-06-10

Snapshot

Financial statements

Quarterly trend

More on Abbott Laboratories

See how VectorShift works for your firm